RxSight (RXST) Long-Term Deferred Tax (2023)

RxSight (RXST) posted Long-Term Deferred Tax of $646000.0 for Q4 2023.

RxSight (RXST) Long-Term Deferred Tax (2023) Analysis & Trends

RxSight's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $646000.0 for Q4 2023.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $646000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $646000.0 (changed N/A YoY) and the FY2023 annual result came in at $646000.0, changed N/A from the prior year.
Long-Term Deferred Tax was $646000.0 for Q4 2023 at RxSight.
Across five years, Long-Term Deferred Tax topped out at $646000.0 in Q4 2023 and bottomed at $646000.0 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	RxSight	221.81 Mn	-196.39 Mn	23.50 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2023	646,000.00